✦ LIBER ✦

Comments on NIH clinical trials valid analysis requirement

✍ Scribed by Curtis L. Meinert

Book ID: 113298161
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 247 KB
Volume: 16
Category: Article
ISSN: 0197-2456
DOI: 10.1016/0197-2456(95)00125-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

NIH Conference on Estrogen and Progestin

NIH Conference on Estrogen and Progestin Clinical Trials

✍ Roberts, Shelagh 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 248 KB

Analysis of clinical trial outcomes: Som

Analysis of clinical trial outcomes: Some comments on subgroup analyses

✍ Marc E. Buyse 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 529 KB

Commentary on meta-analysis in clinical

Commentary on meta-analysis in clinical trials

✍ Jesse Berlin; Thomas C. Chalmers 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 266 KB

Comment on randomised clinical trials in

Comment on randomised clinical trials in breast cancer

✍ T.B. Brewin 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 350 KB

FDA comments on phase I clinical trials

FDA comments on phase I clinical trials without vector biodistribution data

✍ Epstein, Suzanne; Bauer, Steven; Miller, Andra; Pilaro, Anne; Noguchi, Philip 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 83 KB

Some comments on frequently used multipl

Some comments on frequently used multiple endpoint adjustment methods in clinical trials

✍ A. J. Sankoh; M. F. Huque; S. D. Dubey 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

Confirmatory clinical trials often classify clinical response variables into primary and secondary endpoints. The presence of two or more primary endpoints in a clinical trial usually means that some adjustments of the observed p-values for multiplicity of tests may be required for the control of th